Good Long-Term Survival After Childhood Liver Transplant

This article originally appeared here.
Share this content:
Good Long-Term Survival After Childhood Liver Transplant
Good Long-Term Survival After Childhood Liver Transplant

TUESDAY, Dec. 26, 2017 (HealthDay News) -- Liver transplantation in childhood is associated with good long-term survival, according to a study published online Dec. 15 in the American Journal of Transplantation.

Josefina Martinelli, M.D., from the Université Paris-Sud, and colleagues examined the outcomes of 128 children who underwent deceased donor liver transplantation from 1988 to 1993 (median age, 2.5 years). Participants were followed for a median of 24 years.

The researchers found that the 20-year patient survival rate was 79 percent and that the 20-year graft survival rate was 64 percent. Forty-two percent of survivors had elevated serum aminotransferase and/or gamma-glutamyl transferase activities after a single transplantation. In graft histology of 35 patients, 11 showed signs of chronic rejection and and five of biliary obstruction. Patients with abnormal and normal serum liver tests had mean total fibrosis scores of 4.5 and 3 out of 9, respectively. In 35 survivors, including four in end-stage renal disease who were undergoing dialysis or had undergone renal transplantation, the glomerular filtration rate was less than 90 mL/min. The median final heights were 159 and 172 cm for women and men, respectively; in 37 patients, final height was below the target height.

"Twenty-year survival after childhood liver transplantation may be close to 80 percent, and final height is within the normal range for most patients," the authors write. "However, chronic kidney disease or altered liver biochemistries are present in over one-third of patients, which is a matter of concern for the future."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths